Q. What is the plan to move from the offering of solutions in the life science market to the offering of solutions or products in the clinic?
A. There is still a lot of work and research to be done at the genomics level, and we just received FDA 510(k) clearance for a new real-time PCR instrument for use with new flu test from CDC.
I personally think that the future of molecular diagnostics and disease state focus will require the validation and verification of protein biomarkers as well.
Translational medicine, the understanding of the disease state at the molecular level, will focus on the early diagnosis and prevention of disease. Personalized medicine, though based on the underlying genomic makeup, will be monitored and treated at the level of the protein in many cases.
Our investment in mass spec supports the view that this is where the battle will be won. We now have the kind of instrumentation that will enable the tracking of innovative therapeutic approaches like microdosing based on sensitivity and scan speeds.